Navigation Links
Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
Date:8/5/2014

ology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the intended effects and potential impact of SYN-004, the timing of initiation of the Phase Ia and Ib clinical studies, the preliminary Phase I topline data and initiation of Phase II efficacy study and the expected size of the market for C. diff therapeutics. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking s
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... Massachusetts (PRWEB) March 02, 2015 Outside ... services, today announced the addition of Debbie Casey as ... capabilities in the healthcare space. , Debbie ... most of which with Fresenius Medical Care North America ... leverage her extensive experience to work with Outside GC’s ...
(Date:2/27/2015)... GERMANTOWN, Md. and SUMMERLAND, British ... Corporation (NYSE: XON ), a leader ... an agreement to acquire  Okanagan Specialty Fruits (OSF), ... apple , the world,s first non-browning apple. Through ... trees yielding fruit that is more appetizing and convenient ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Outside GC Expands Healthcare Team 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... November 1, 2011 - Listed companies to present ... 30 - December 2 Elsevier Business Intelligence ... to Watch list. The list delivers projects and companies with ... growth through investments in deals. This year,s list includes ...
... Colo., Oct. 31, 2011 Azantis launches today AstaKrill™ ... Azantis , a leading krill oil manufacturer, markets AstaKrill to ... antioxidant that gives krill its distinct red color. The astaxanthin ... in other krill oils currently on the market. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Opportunity Assessment and Market Forecasts to ... Spinal Implants - ...
Cached Biology Technology:Windhover Announces the "Top Biopharma Projects to Watch" 2Windhover Announces the "Top Biopharma Projects to Watch" 3AstaKrill™ the Best Krill Oil Boosts Astaxanthin 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... SALT LAKE CITY -- Climate change spells trouble ... mountains, coastal forests and relatively small areas and ... habitat loss, disease and competition among species. That ... 200 scientific studies relevant to the topic. The review ...
... To maintain power, oil-rich governments often lean on their ... damage their companies, efficiency and raise prices for the ... Mark Thurber. The state-owned oil companies, like Saudi ... control 73 percent of the world,s oil reserves, dwarfing ...
... NY, February 15, 2012Therapeutic cancer vaccines, which stimulate ... cancer cells, are being used in combination with ... several illuminating articles in Cancer Biotherapy and ... Liebert, Inc. ( http://www.liebertpub.com ). These articles are ...
Cached Biology News:Climate change threatens tropical birds 2Climate change threatens tropical birds 3Climate change threatens tropical birds 4Climate change threatens tropical birds 5Book examines state-owned oil firms, prices and pollution 2Book examines state-owned oil firms, prices and pollution 3Promising early results with therapeutic cancer vaccines 2
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 5,000 units polymerase, 25 ...
Biology Products: